Jump to navigation Jump to search

Clinical data
ATC code
Pharmacokinetic data
Elimination half-life16-34 hours
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass441.541 g/mol

WikiDoc Resources for Troglitazone


Most recent articles on Troglitazone

Most cited articles on Troglitazone

Review articles on Troglitazone

Articles on Troglitazone in N Eng J Med, Lancet, BMJ


Powerpoint slides on Troglitazone

Images of Troglitazone

Photos of Troglitazone

Podcasts & MP3s on Troglitazone

Videos on Troglitazone

Evidence Based Medicine

Cochrane Collaboration on Troglitazone

Bandolier on Troglitazone

TRIP on Troglitazone

Clinical Trials

Ongoing Trials on Troglitazone at Clinical

Trial results on Troglitazone

Clinical Trials on Troglitazone at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Troglitazone

NICE Guidance on Troglitazone


FDA on Troglitazone

CDC on Troglitazone


Books on Troglitazone


Troglitazone in the news

Be alerted to news on Troglitazone

News trends on Troglitazone


Blogs on Troglitazone


Definitions of Troglitazone

Patient Resources / Community

Patient resources on Troglitazone

Discussion groups on Troglitazone

Patient Handouts on Troglitazone

Directions to Hospitals Treating Troglitazone

Risk calculators and risk factors for Troglitazone

Healthcare Provider Resources

Symptoms of Troglitazone

Causes & Risk Factors for Troglitazone

Diagnostic studies for Troglitazone

Treatment of Troglitazone

Continuing Medical Education (CME)

CME Programs on Troglitazone


Troglitazone en Espanol

Troglitazone en Francais


Troglitazone in the Marketplace

Patents on Troglitazone

Experimental / Informatics

List of terms related to Troglitazone

Troglitazone (Rezulin®, Resulin® or Romozin®) is a member of the drug class of the thiazolidinediones. It was introduced in the late 1990s but turned out to be associated with an idiosyncratic reaction leading to drug-induced hepatitis. It was withdrawn from the USA market on 21 March 2000, and from other markets soon afterwards.

Troglitazone, like the other thiazolidinediones (pioglitazone and rosiglitazone), works by activating PPARs (peroxisome proliferator-activated receptors). Troglitazone is a ligand to both PPARα and - more strongly - PPARγ. Troglitazone also contains an α-tocopheroyl moiety, potentially giving it vitamin E-like activity in addition to its PPAR activation. It has been shown (Aljada et al) to reduce inflammation: troglitazone use was associated with a decrease of nuclear factor kappa-B (NFκB) and a concomitant increase in its inhibitor (IκB). NFκB is an important cellular transcription regulator for the immune response.


  • Aljada A., Garg R., Ghanim H., Mohanty P., Hamouda W., Assian E., Dandona P.: Nuclear factor-κB suppressive and inhibitor-κB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J. Clin. Endocrinol. Metab. 2001, 86, 3250-6. Fulltext. PMID 11443197.

See also

External links

Template:Oral hypoglycemics

Template:WikiDoc Sources